What is Sequella?
Sequella is a clinical-stage biopharmaceutical firm dedicated to creating advanced antibiotic therapies to combat the escalating threat of drug-resistant bacterial, fungal, and parasitic infections. The company's strategic focus is on tackling major global health crises, particularly multidrug-resistant tuberculosis (TB), a condition affecting billions worldwide. With promising drug candidates like SQ109 and sutezolid having advanced through Phase 2 clinical trials, Sequella is poised to deliver much-needed therapeutic solutions. Their research also extends to treatments for other severe infectious diseases, including those caused by Clostridium difficile and various parasitic agents, highlighting their commitment to broad-spectrum infectious disease control.
How much funding has Sequella raised?
Sequella has raised a total of $11.9M across 11 funding rounds:
Debt
$2M
Multiple Rounds
$1.6M
Unspecified
$100K
Unspecified
$555K
Debt
$3.1M
Private Equity
$1.7M
Private Equity
$630K
Debt (2010): $2M, investors not publicly disclosed
Debt (2011): $1M featuring Easton Capital Partners
Unspecified (2011): $550K backed by Easton Capital Partners
Debt (2011): $50K with participation from Easton Capital Partners
Unspecified (2012): $100K led by Easton Capital Partners
Unspecified (2013): $555K supported by Easton Capital Partners
Debt (2014): $3.1M, investors not publicly disclosed
Private Equity (2016): $1.7M, investors not publicly disclosed
Private Equity (2017): $630K, investors not publicly disclosed
Key Investors in Sequella
Easton Capital Partners
Easton Capital Partners is an investment group managing approximately $200 million across multiple funds. They specialize in making investments ranging from $2 million to $7.5 million and leverage strategic co-investment relationships for larger funding rounds.
What's next for Sequella?
The substantial enterprise-level backing and recent strategic investment indicate Sequella is in a scaling phase, likely preparing for later-stage clinical trials and potential commercialization. This infusion of capital will be critical for advancing their lead candidates through the rigorous regulatory approval process and expanding their research into other challenging infectious diseases. Sequella's continued focus on drug-resistant pathogens positions them as a key player in a market with urgent unmet medical needs, suggesting a trajectory towards significant growth and impact in global public health.
See full Sequella company page
